Charles Schwab
PRME icon

Charles Schwab’s Prime Medicine PRME Stock Holding History

Charles Schwab’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.42M Buy
927,538
+10,326
+1% +$34.3K ﹤0.01% 2621
2026
Q1 		$3.19M Sell
917,212
-19,603
-2% -$74.6K ﹤0.01% 2583
2025
Q4 		$3.25M Buy
936,815
+363,657
+63% +$1.62M ﹤0.01% 2609
2025
Q3 		$3.18M Buy
573,158
+54,530
+11% +$222K ﹤0.01% 2623
2025
Q2 		$1.28M Buy
518,628
+14,931
+3% +$23K ﹤0.01% 2823
2025
Q1 		$1M Buy
503,697
+19,106
+4% +$48.7K ﹤0.01% 2840
2024
Q4 		$1.42M Buy
484,591
+20,614
+4% +$72.4K ﹤0.01% 2790
2024
Q3 		$1.8M Sell
463,977
-28,284
-6% -$131K ﹤0.01% 2742
2024
Q2 		$2.53M Buy
492,261
+194,438
+65% +$1.18M ﹤0.01% 2622
2024
Q1 		$2.08M Buy
297,823
+1,635
+0.6% +$12.4K ﹤0.01% 2582
2023
Q4 		$2.62M Buy
296,188
+3,618
+1% +$27.9K ﹤0.01% 2532
2023
Q3 		$2.79M Buy
292,570
+151,426
+107% +$1.97M ﹤0.01% 2502
2023
Q2 		$2.07M Buy
141,144
+67,717
+92% +$945K ﹤0.01% 2540
2023
Q1 		$903K Buy
73,427
+2,243
+3% +$36.5K ﹤0.01% 2767
2022
Q4 		$1.32M Buy
+71,184
New +$1.29M ﹤0.01% 2688

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Charles Schwab's PRME Position: Q2 2026 in Review

Charles Schwab increased its Prime Medicine (PRME) stake by 1.1% in Q2 2026, buying an estimated $34.3K and bringing the position to 927,538 shares worth $3.42M. The position accounts for ﹤0.01% of the portfolio, ranked #2621.

Charles Schwab first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Charles Schwab held 927,538 shares of Prime Medicine worth $3.42M as of Q2 2026.
  • Charles Schwab bought 10,326 Prime Medicine shares in Q2 2026, an estimated $34.3K.
  • Prime Medicine made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2621 holding.
  • Charles Schwab first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.